Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Videos|March 30, 2026

DCAT Week 2026: Where is the CDMO Market Heading?

In the final part of the interview, Franco Negron, CEO, Simtra BioPharma Solutions notes the question frequently heard from sponsors and predicts where the CDMO market is heading.

In the final part of his conversation with BioPharm International, Franco Negron, CEO of Simtra, discusses the company’s aggressive investment strategy, expertise in high‑complexity manufacturing, and broader CDMO market trends in this in‑depth DCAT Week interview.

With more than 35 years in manufacturing across OTCs and pharmaceuticals, including senior leadership roles at Thermo Fisher Scientific, Franco Negron explains how Simtra’s investment thesis was built around early, large‑scale capital deployment to meet fast‑growing demand in biologics and bioconjugation, particularly antibody-drug conjugates (ADCs). Backed by private equity sponsors Warburg Pincus and Advent International, Simtra has invested nearly $500 million post‑acquisition to expand capacity and capabilities.

Negron highlights Simtra’s leadership in ADC fill‑finish at its Halle, Germany site as a key to integrating upstream and downstream expertise. Looking ahead, Negron sees the CDMO sector becoming more proactive, innovation‑driven, and collaborative, with growing focus on AI, advanced technologies, stronger quality systems, and honest peer‑to‑peer dialogue that delivers real value to customers and patients.

About the speaker

Franco Negron, CEO, Simtra Biopharma Solutions

With more than 2 decades of executive leadership experience, Negron is a seasoned industry expert and a passionate advocate for the purpose that drives Simtra: to bring vital injectable products to patients worldwide. Negron’s tenure as CEO of ApiJect Systems, a global medical technology company, and his role as president of Commercial Operations at Thermo Fisher Scientific, have equipped him with a deep understanding of the pharmaceutical manufacturing landscape. His leadership is marked by a collaborative spirit and a relentless drive to push the industry’s boundaries while fostering an environment that values integrity, quality and teamwork. His previous roles include vice president of Manufacturing and Supply at Valeant Pharmaceuticals, global vice president in Novartis’ Consumer Health division, and site general manager at McNeil Consumer Healthcare.


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.